National Donor Deferral Registry (NDDR) Helps Ensure That Deferred Donors Cannot Donate Their Plasma Again
The National Donor Deferral Registry (NDDR) is a database of permanently deferred plasma donors in North America. It is one of many voluntary, self-regulating initiatives taken by the source plasma collection industry and is an important component of the industry-driven safety measures taken to help ensure the safety of the final therapies.
All donors who test "reactive" for the viral agents for HIV, HBV and HCV are added to the NDDR and are permanently prohibited from donating source plasma at participating licensed and industry-certified centers in the U.S. and Canada.
The NDDR first was made available to all blood and source plasma facilities in December 1993. Haemonetics, a valued partner of PPTA, is responsible for the administration and customer support services of the NDDR.
All inquires should be directed to the NDDR Customer Support Desk at 1-877-534-3578.
PPTA Recognizes 8th Annual International Rare Disease Day +
The Plasma Protein Therapeutics Association joins more than 300 organizations in 56 countries in recognizing the 8th annual International Rare Disease Day on February 28.
Sponsored by the National Organization of Rare Disorders and Rare Diseases Europe, Rare Diseases Day seeks to raise awareness among the general public and policymakers about rare diseases, impacting lives all over the globe.Read More
PPTA Introduces New Cross Donation Check System +
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) recently launched the Cross Donation Check System (CDCS), a new electronic database designed to assist plasma centers in checking donors more efficiently and effectively.Read More
Ensuring Access to Medicines for Patients: Pharmaceutical Industry Associations Release ‘Principles for Communication of Information on Quality and Manufacturing Potential Supply Disruption’ +
(20th January 2015 – Brussels) – AESGP, EFPIA, EGA, and PPTA are pleased to announce today’s release of the joint principles for “Communication of information on quality and manufacturing potential supply disruption”. This document forms part of the industry response to the EMA (European Medicines Agency) call for voluntary and proactive action, to provide European patients with continuous access to medicines.Read More
PPTA Standards Programs